Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1

n/a

Bibliographic Details
Main Authors:	Miranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen
Format:	Article
Language:	English
Published:	MDPI AG 2018-05-01
Series:	Journal of Personalized Medicine
Subjects:	n/a
Online Access:	http://www.mdpi.com/2075-4426/8/2/17

Similar Items

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19
by: Miranta Antoniou, et al.
Published: (2018-05-01)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
by: Miranta Antoniou, et al.
Published: (2016-01-01)

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
by: Miranta Antoniou, et al.
Published: (2017-01-01)

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
by: Miranta Antoniou, et al.
Published: (2017-12-01)

Biomarker-guided clinical trial designs
by: Antoniou, Miranta
Published: (2018)

Statistical shape analysis for bilateral symmetry
by: Ruwanthi, Kolamunnage Dona Rasanga
Published: (2005)

Meminductor Emulator Based on a Modified Antoniou’s Gyrator Circuit
by: Francisco J. Romero, et al.
Published: (2020-09-01)

Biomarker-guided trials: Challenges in practice
by: M. Antoniou, et al.
Published: (2019-12-01)

Bayesian joint modelling of longitudinal and time to event data: a methodological review
by: Maha Alsefri, et al.
Published: (2020-04-01)

joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes
by: Graeme L. Hickey, et al.
Published: (2018-06-01)

Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues
by: Graeme L. Hickey, et al.
Published: (2016-09-01)

Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
by: Arinjita Bhattacharyya, et al.
Published: (2019-09-01)

Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW
by: Chang Ming, et al.
Published: (2020-04-01)

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
by: Maria Sudell, et al.
Published: (2016-12-01)

Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
by: Maria Sudell, et al.
Published: (2018-04-01)

Time-dependent ROC curve analysis in medical research: current methods and applications
by: Adina Najwa Kamarudin, et al.
Published: (2017-04-01)

Theodore Antoniou| The Greek components of his music for flute and an analytical presentation of his work "Lament for Michelle," for solo flute
by: Fourla, Vasiliki
Published: (2016)

Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials
by: Jay JH. Park, et al.
Published: (2019-09-01)

Update of the Navy Contract Writing Guide Phase III
by: Schwartz, Brett M., et al.
Published: (2013)

Update of the Navy Contract Writing Guide Phase III
by: Schwartz, Brett M., et al.
Published: (2005)

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT
by: Sudeep Pushpakom, et al.
Published: (2019-07-01)

Assessing the potential for outcome reporting bias in a review: a tutorial
by: Powell Colin, et al.
Published: (2010-05-01)

Optimal decision criteria for the study design and sample size of a biomarker-driven phase III trial
by: Takazawa, Akira
Published: (2020)

Utility-based optimization of phase II / phase III clinical development
by: Aouni, Jihane
Published: (2019)

Polymorphisms and Differential Expression of Phase II and Phase III Detoxification Proteins
by: Yu-ching Wang, et al.
Published: (2006)

Spatial Linear Mixed Effects Modelling for OCT Images: SLME Model
by: Wenyue Zhu, et al.
Published: (2020-06-01)

SCIENTIFIC PROCESSUALISM AND “METHODOLOGICAL PHASES OF THE PROCESS”: THE ERISTIC TACTIC OF THE SCIENTIFIC ADJECTIVE AND THE “NEW METHODOLOGICAL PHASES”
by: Igor Raatz, et al.
Published: (2020-12-01)

The superconducting phase diagram of the t-J model
by: Ubbens, Menke Ubbo Heert
Published: (2006)

Update of the Navy Contract Writing Guide Phase III: creation of an addendum addressing DD-1716 contract deficiencies
by: Schlegel, Kevin A.
Published: (2012)

Per-Phase and 3-Phase Optimal Coordination of Directional Overcurrent Relays Using Genetic Algorithm
by: Ronald C. Matthews, et al.
Published: (2021-03-01)

Investigation of Fe(III)-As(III) bearing phases and their potential for arsenic disposal
by: Opio, FAITH
Published: (2013)

Phase III clinical trials: No ethics no paradigm
by: Jhony A. De La Cruz-Vargas
Published: (2021-03-01)

Workload Accomplished in Phase III Cardiac Rehabilitation
by: Katrina L. Schultz, et al.
Published: (2021-05-01)

Project 8 Phase III Design Concept
by: Esfahani, A Ashtari, et al.
Published: (2019)

Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children
by: Irwin Adam D, et al.
Published: (2012-05-01)

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
by: Ting Martin Ma, et al.
Published: (2021-05-01)

Transactivation of Genes Encoding for Phase II Enzymes and Phase III Transporters by Phytochemical Antioxidants
by: Sang Geon Kim, et al.
Published: (2010-09-01)

Polymorphism and Differential Expression of Phase Ⅱ and Phase Ⅲ Detoxification Proteins in Hepatoma Tissues
by: Ya-fen Shiau, et al.
Published: (2007)

Minimum Loss Discontinuous Pulse-Width Modulation Per Phase Method for Three-Phase Four-Leg Inverter
by: Soo Yeon Kim, et al.
Published: (2020-01-01)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
by: Linda Spiegelberg, et al.
Published: (2019-02-01)